Biovest International, Inc. developed active immunotherapies to treat and diminish the aggressiveness of B-cell non-Hodgkin's lymphoma. The company has been involved in innovative, cost-effective, and scalable GMP custom mammalian cell and protein production.
Focus Areas
Notable Investments
